Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $12.31 million versus the consensus estimate of $14.43 million.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.